Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously treated metastatic renal cell carcinoma patients. This analysis provides insight on current use of approved therapies for renal cell carcinoma in the United States and on oncologists’ perception of these therapies.
Renal Cell Carcinoma - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (US) 2020
This report is available to find out more click the link and fill out the form to get more details.
Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (US)
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angi...
Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...
Renal Cell Carcinoma - Epidemiology - Mature Markets
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across the major mature pharmace...